Executives On The Move: Bio/Med Changes Made From Lilly And Amgen, And A Step Up R&D Ladder At Daiichi Sankyo
Executive Summary
Eli Lilly & Co’s Biology VP takes on SVP, Discovery role at gene regulatory mechanism firm Fulcrum Therapeutics, and Amgen Med Affairs exec becomes CMO at Matinas BioPharma Holdings. At Daiichi Sankyo, R&D leader steps up to Global Head, R&D position.